CT Evaluation of Effects of Cranial Radiation Therapy in Children

Patricia C. Davis, James C. Hoffman, Jr., Gary S. Pearl and Ira F. Braun

*AJNR Am J Neuroradiol* 1986, 7 (4) 639-644

http://www.ajnr.org/content/7/4/639

This information is current as of July 13, 2023.
CT Evaluation of Effects of Cranial Radiation Therapy in Children

Patricia C. Davis, James C. Hoffman, Jr., Gary S. Pearl, Ira F. Braun

A retrospective evaluation was completed of 49 children who received conventional cranial radiation therapy for primary central nervous system and/or skull-base neoplasia and who had follow-up CT studies. In these children, abnormalities in normal parenchyma away from the tumor itself were surprisingly frequent, with or without chemotherapy. Generalized volume loss or atrophy was the most frequent abnormality (51%), but in this population it may have resulted from a variety of causes. Calcification in nontumorous parenchyma was common (28%) with or without chemotherapy. The most frequent site of calcification was subcortical at the gray-white junction. Calcification was progressive over 1–2 years and correlated pathologically with mineralizing microangiopathy and dystrophic calcification with demyelination. White-matter abnormalities other than those associated with shunt malfunction and tumor edema occurred in 26% of the patients. Both white-matter abnormalities and calcification occurred predominantly in younger children, particularly those under 3 years old at the time of radiation therapy. Of the 21 children who received chemotherapy in this series, only two received methotrexate. White-matter abnormalities and calcifications occurred with similar frequency in children with and without chemotherapy; thus, radiation therapy is the most likely cause of these findings.

Cranial radiation therapy is a standard component of treatment for children with central nervous system (CNS) neoplasia. However, the long-term effects of this therapy on the developing brain are only recently being recognized. The literature [1–5] describes a decline in neuropsychological skills after radiation therapy, but the source of this decline is unclear. Pathologic studies [3, 6–10] suggest that radiation-induced abnormalities at therapeutic levels of radiation therapy are uncommon, or are exacerbated by the synergistic effect of chemotherapy, particularly methotrexate [11–25].

In this study a retrospective evaluation was completed of children who received therapeutic radiation for CNS neoplasia to determine (1) the frequency of CT abnormalities occurring in normal brain and (2) the contribution of radiation therapy to these abnormalities.

Materials and Methods

A retrospective review was completed of all children with primary CNS or skull-base neoplasia who underwent cranial radiation therapy between 1979 and 1982 (53 children). Only those with a follow-up CT examination at least 3 months after radiation therapy were included (mean follow-up time = 2.3 years, range = 3 months to 5½ years). Forty-nine children met these criteria.

Charts were reviewed to determine the surgical procedures performed; histologic diagnosis; age at time of radiation therapy; dose, fractionation, and portal of treatment; dates and types of chemotherapy administered; and clinical status at last follow-up visit.

CT scans were reviewed for abnormalities unrelated to the tumor itself. Abnormalities evaluated included presence, location, and progression of calcification; presence and location of white-matter abnormalities; focal or generalized atrophy; hydrocephalus; and infarction.
White-matter abnormalities related to tumor edema and/or shunt malfunction were excluded. Atrophy was described only when sulci, cisterns, and ventricles were enlarged consistently over a period of time proportionate to the child's age.

Nonneoplastic tissue, obtained after radiation therapy, was available from seven children, including three with complete postmortem examination of the CNS. This tissue was evaluated histologically, and results were correlated with radiographic and clinical findings.

Results

Forty-nine children ranging in age from 6 weeks to 17 years at the time of presentation were evaluated in this study. Diagnoses, histologic location, and radiation dose are charted in Table 1. Mean age at the time of radiation therapy was 7½ years (range 3 months to 17 years). Fractionation of radiation dose was less than or equal to 200 rads per day. Twenty-eight children were treated with surgery and radiation alone, and 21 children also received one or more courses of chemotherapy. Chemotherapeutic agents administered varied in type, dose, and route of administration. Only two children received methotrexate. Many children received acute steroid therapy during radiation therapy; however, none were on chronic steroid therapy. Many were maintained on chronic phenobarbital and/or phenytoin for seizure control or prophylaxis. Thirty-nine patients had ventricular shunts for hydrocephalus.

CT abnormalities encountered in nontumorous parenchyma are correlated with age at the time of radiation therapy and chemotherapy in Table 2. Atrophy for age was the most frequent abnormality encountered (Fig. 1), and was usually

### Table 1: Histologic Diagnosis, Location, and Radiation Dose

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Location</th>
<th>Dose (Rads)</th>
<th>Whole Brain</th>
<th>Tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medulloblastoma</td>
<td>Posterior fossa (17)</td>
<td>2550–4040</td>
<td>4500–5480</td>
<td></td>
</tr>
<tr>
<td>Meduloneuroblastoma</td>
<td>Posterior fossa (1)</td>
<td>3500</td>
<td>4450</td>
<td></td>
</tr>
<tr>
<td>Astrocytoma:fibrillary/pilocytic</td>
<td>Pons: no biopsy (2)</td>
<td>5000 (1)</td>
<td>4484 (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypothalamus/chiasm (5)</td>
<td>4140–5600 (4)</td>
<td>3960 (1)</td>
<td></td>
</tr>
<tr>
<td>Glioblastoma multiforme</td>
<td>Thalamus; no biopsy (1)</td>
<td>—</td>
<td>5000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brainstem (1)</td>
<td>—</td>
<td>5000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rt. cereb. hemis. (1)</td>
<td>—</td>
<td>6100</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lt. cereb. hemis. (1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primitive neuroectoderm (malignant small cell)</td>
<td>Rt. front lobe (1)</td>
<td>3960</td>
<td>5610</td>
<td></td>
</tr>
<tr>
<td>Small-cell sarcoma</td>
<td>Thalamus (1)</td>
<td>—</td>
<td>5610</td>
<td></td>
</tr>
<tr>
<td>Ependymoma</td>
<td>4th cranial nerve (4)</td>
<td>3910–4980</td>
<td>4420–4800</td>
<td></td>
</tr>
<tr>
<td>Ependymoma, malignant</td>
<td>Lt. cereb. hemis. (2)</td>
<td>—</td>
<td>5500–5580</td>
<td></td>
</tr>
<tr>
<td>Gangliocytoma</td>
<td>4th ventricle (2)</td>
<td>3520</td>
<td>4800</td>
<td></td>
</tr>
<tr>
<td>Melanoma, malignant</td>
<td>Rt. front lobe (1)</td>
<td>—</td>
<td>5500</td>
<td></td>
</tr>
<tr>
<td>Pineal</td>
<td>Rt. temporal–parietal (1)</td>
<td>4050</td>
<td>5550</td>
<td></td>
</tr>
<tr>
<td>Pineal</td>
<td>Pineal; no biopsy (3)</td>
<td>4000</td>
<td>1000–1500</td>
<td></td>
</tr>
<tr>
<td>Craniopharyngioma</td>
<td>Suprasellar (1)</td>
<td>—</td>
<td>5700</td>
<td></td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>Rt. front lobe (1)</td>
<td>5000</td>
<td>5800</td>
<td></td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>Both lateral vent. (1)</td>
<td>5000</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Teratoma</td>
<td>Suprasellar &amp; lt. temporal (1)</td>
<td>3500</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Juvenile fibroma</td>
<td>Rt. orbit (1)</td>
<td>—</td>
<td>5500</td>
<td></td>
</tr>
<tr>
<td>Esthesioneuroblastoma</td>
<td>Sphenoid, lt. orbit, maxillary sinus (1)</td>
<td>—</td>
<td>5000</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2: CT Abnormalities Correlated with Age at Time of Radiation Therapy and Chemotherapy

<table>
<thead>
<tr>
<th>Chemotherapy</th>
<th>&lt;3 yr (n = 14)</th>
<th>3–12 yr (n = 22)</th>
<th>&gt;12 yr (n = 13)</th>
<th>Totals (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrophy:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;3 yr</td>
<td>+ 3</td>
<td>6</td>
<td>6 (43)</td>
<td></td>
</tr>
<tr>
<td>3–12 yr</td>
<td>6</td>
<td>12 (54)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;12 yr</td>
<td>2 (1*)</td>
<td>7 (54)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>13 (26)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 2: CT Abnormalities Correlated with Age at Time of Radiation Therapy and Chemotherapy

<table>
<thead>
<tr>
<th>Calcifications</th>
<th>&lt;3 yr</th>
<th>3–12 yr</th>
<th>&gt;12 yr</th>
<th>Totals (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;3 yr</td>
<td>+ 2</td>
<td>6</td>
<td>8 (57)</td>
<td></td>
</tr>
<tr>
<td>3–12 yr</td>
<td>3</td>
<td>4</td>
<td>4 (18)</td>
<td></td>
</tr>
<tr>
<td>&gt;12 yr</td>
<td>+ 2 (1*)</td>
<td>0</td>
<td>2 (15)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>14 (28)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note.—The presence (+) or absence (−) of CT abnormalities is correlated with age in years at the time of radiation therapy on the vertical axis and with whether (+) or not (−) chemotherapy was administered on the horizontal axis.

* Two children received methotrexate as part of their chemotherapy; abnormalities in these children are in parentheses.
Infarction was encountered in only two children. Both had large chiasmal/hypothalamic gliomas; thus, their infarcts were not clearly related to radiation therapy [26]. Of these, one with bilateral middle cerebral artery infarcts developed extensive calcification in the infarcted tissue (Fig. 5).

No secondary neoplasms were identified in radiated tissue in this series.

Available information about intelligence and functional level was obtained from chart review; thus, detailed testing was not performed. Five children who showed no CT evidence of recurrent or residual tumor were intellectually and/or functionally impaired.

Nonneoplastic tissue was available for histologic examination after radiation therapy in seven children (four biopsy specimens, three autopsy). All demonstrated multiple abnormalities typical of radiation effects in normal tissue, including gliosis, demyelination, vascular fibrosis and/or fibrinoid necrosis, and calcification both in the neuropil and in or around vessels (Fig. 6). These changes were most striking in tissue near the neoplasm, but the extent of each change was variable from case to case. Six of the seven children had atrophy by CT with no histologic correlate. Only two had visible calcification on CT (one in basal ganglia, one in extensive infarctions); thus, the predilection for calcifications at the gray-white junction noted by CT could not be confirmed pathologically. Three specimens contained perivascular and/or dystrophic calcifications histologically that were not visible on CT. By CT, only one child of the seven had white-matter
generalized in distribution. Because the CT appearance of volume loss could vary from scan to scan, atrophy was described only when seen on multiple studies. Atrophy incidence varied little with age or administration of chemotherapy. Seventeen children had generalized atrophy as the only CT abnormality unrelated to the tumor itself.

Focal (three cases) or generalized (10 cases) areas of decreased white-matter attenuation were identified in 26% of the patients (Fig. 2). Nine of these also had focal calcifications. White-matter abnormalities occurred in nine patients who were younger than 12 years old. Two of the four children older than 12 years with white-matter abnormalities had received methotrexate. White-matter abnormalities were always within the radiation portal and were identified in children who had never received chemotherapy. Radiation dosage in this group ranged from 2600-5000 rads.

Calcifications in nontumorous parenchyma were identified in 14 children (Fig. 3), appearing as early as 3 months after radiation therapy. These tended to occur in younger children, with or without chemotherapy. Calcification occurred most frequently at the gray-white junction of the cerebral hemispheres followed by the basal ganglia, with one patient each having calcification in the caudate nucleus and cerebellum. In six children, calcification progressed in extent and density (Fig. 4). Calcification was encountered without CT evidence of white-matter disease or atrophy in four patients. Radiation doses in children with calcification ranged from 3500-5500 rads.

Infarction was encountered in only two children. Both had large chiasmal/hypothalamic gliomas; thus, their infarcts were not clearly related to radiation therapy [26]. Of these, one with bilateral middle cerebral artery infarcts developed extensive calcification in the infarcted tissue (Fig. 5).

No secondary neoplasms were identified in radiated tissue in this series.

Available information about intelligence and functional level was obtained from chart review; thus, detailed testing was not performed. Five children who showed no CT evidence of recurrent or residual tumor were intellectually and/or functionally impaired.

Nonneoplastic tissue was available for histologic examination after radiation therapy in seven children (four biopsy specimens, three autopsy). All demonstrated multiple abnormalities typical of radiation effects in normal tissue, including gliosis, demyelination, vascular fibrosis and/or fibrinoid necrosis, and calcification both in the neuropil and in or around vessels (Fig. 6). These changes were most striking in tissue near the neoplasm, but the extent of each change was variable from case to case. Six of the seven children had atrophy by CT with no histologic correlate. Only two had visible calcification on CT (one in basal ganglia, one in extensive infarctions); thus, the predilection for calcifications at the gray-white junction noted by CT could not be confirmed pathologically. Three specimens contained perivascular and/or dystrophic calcifications histologically that were not visible on CT. By CT, only one child of the seven had white-matter
hypolucency; this correlated histologically with extensive vascular fibrosis, calcification, and gliosis. The other six children had histologically identifiable white-matter abnormalities that were not apparent on CT.

**Discussion**

Although radiation therapy is of significant value in the management of children with primary CNS neoplasia, the long-term effects on survivors are unclear. Pathologic studies describe adverse effects of radiation therapy as uncommon both in adults and children [3, 6–10]; however, adverse effects in survivors are largely undocumented. Likewise, CT abnormalities in survivors may not be confirmed by biopsy and/or resection; thus, the true incidence of radiation-induced lesions is unknown. Many reports document the adverse effects of radiation therapy with large single or cumulative radiation dosages, or with daily fractions of greater than 200 rads [3, 6], but the relationship between these examples and conventional radiation therapy is unclear. To further complicate the issue, patients may also receive chemotherapeutic agents with known adverse effects on normal parenchyma or that have a synergistic effect with radiation therapy.

In children surviving acute lymphocytic leukemia, the adverse effects demonstrable by CT and pathology of methotrexate combined with low doses of radiation therapy are well documented [12–25, 27]. A synergistic effect exists between intrathecal or intravenous methotrexate and low levels of radiation, resulting in damage to normal parenchyma. Abnormalities include white-matter necrosis and mineralizing microangiopathy with secondary decreased intellectual function [5]. The sequelae in children treated with radiation therapy alone, however, are less clear.

In this series, primary goals were to identify abnormalities

![Fig. 3.-Basal ganglia and gray-white junction calcification in a 4-year-old child treated for medulloblastoma at age 7 months with 3420 rads.](image1)

![Fig. 4.—A. Calcifications first identified 7 months after radiation therapy for medulloblastoma (4930 rads at age 2½ years) progressed in extent and density over a 3-year follow-up (B). C, Noncontrast CT confirms calcifications.](image2)
apart from the tumor itself and to determine the relationship between these and the child's age at the time of radiation therapy and chemotherapy. The most frequent abnormality encountered (51%) was generalized volume loss or atrophy for the child's age. Although radiation therapy may be contributory, it is difficult to attribute atrophy to radiation alone. In this population, chemotherapy, other drugs (i.e., steroids and phenytoin), repeated episodes of increased intracranial pressure, postoperative subdural hygromas and/or hematomas, and nutritional disorders may be contributory. Furthermore, with serial CT studies "atrophy" may be transient or variable in degree.

The frequency of calcification on CT in nontumorous tissue in this series was surprising (28%). Interestingly, six of seven children with histologic evaluation showed significant calcification at the microscopic level. Calcification of the basal ganglia after radiation therapy is well recognized [28]. In this series, however, the most frequently identified site of calcification was subcortical at the gray-white junction, perhaps because of the image quality of high-resolution later-generation CT. Calcifications could be progressive over 1–2 years. Correlation with available pathology suggested that this subcortical calcification was a result of radiation-induced vasculopathy with perivascular calcification (mineralizing microangiopathy) or with demyelination and tissue necrosis followed by dystrophic calcification. Although mineralizing microangiopathy and dystrophic calcification are thought to be specific for the combination of methotrexate and radiation therapy [13, 24], in this series these pathologic abnormalities occurred with radiation alone.

White-matter abnormalities were identified in 26% of radiated children. White-matter abnormalities after radiation and methotrexate have been described [3, 12, 14, 17, 19, 21, 25]; however, in this group only two children received methotrexate. White-matter abnormalities tended to occur in younger children, particularly those under 3 years old, with or without chemotherapy. A rapid phase of myelination occurs in early childhood, so it is predictable that radiation therapy would adversely affect the proliferating glial elements in young children [6].

Premature atherosclerotic and arteriosclerotic vascular disease and even a moyamoya appearance have been attributed to radiation therapy [29–31]. In this series, however, the only infarcts encountered were in children with chiasmal and/or hypothalamic tumors. In our experience, these tumors may encase and obliterate major vessels at the skull base in the absence of radiation therapy [26]. Thus, the infarcts in this series cannot definitely be attributed to radiation.

A synergistic effect on tissue has been described with radiation and ischemia [6, 9]. This was apparent in one child who developed extensive calcification in infarcted tissue after radiation therapy.

Tumor induction from radiation therapy has a latency period of up to 15 years [32–36]; thus, the absence of new or secondary neoplasms in this series with a mean follow-up of 2.3 years is not surprising.

Radiation necrosis may result in frank disruption of the blood-brain barrier with contrast enhancement and mass effect mimicking tumor recurrence [21–22, 24, 37]. This was suspected but not documented in one patient in our series. The possibility exists that radiation necrosis may have been responsible for enhancing masses seen in children in this series who were not surgically reevaluated.

Of major significance is the clinical impact of the CT abnormalities identified. In the absence of detailed clinical testing, deficits cannot be clearly related to the abnormalities identified. The five children with deficits but with no evidence of residual or recurrent tumor were of concern and warrant further study.

In summary, in our series, adverse effects on nontumorous parenchyma by CT after radiation therapy in the pediatric population were not unusual. In this series, 39% of patients had white-matter abnormalities and/or calcifications whether...
or not chemotherapy was administered. If atrophy is also considered, 73% of children evaluated had abnormalities unrelated to the tumor itself. Only two children received methotrexate; thus, a synergistic effect between methotrexate and radiation therapy cannot be implicated. Radiation therapy alone was the primary therapeutic modality associated with white-matter abnormalities and calcification. These abnormalities were more frequent and more severe in younger children, particularly those who received radiation therapy when they were younger than 3 years old.

ACKNOWLEDGMENT

The authors gratefully acknowledge the expert assistance of Francine Hollowell and photographer Joe Jackson.

REFERENCES

21. Wang A, Skiias DD, Rumbaugh CL, Schoene WC, Zamani A. Central nervous system changes after radiation therapy and/or chemotherapy: correlation of CT and autopsy findings. AJNR 1983;4:466–471
33. Sandler DP, Comstock GW, Matanoski GN. Neoplasms following childhood radium irradiation of the nasopharynx. JNCI 1982;68:3–8